CompletedNCT00734578

Efficacy and Safety of SPD503 in Combination With Psychostimulants

Medication studyAges 6–17United StatesADHD

The study in practice

Understand this study

Listed age limits: 6 years to 17 years.

Listed locations: Dothan, United States · Scottsdale, United States and 54 more locationsSee all locations and recruitment
Activities: Medication described in the protocol · Placebo comparator
Compensation: Payment and expense reimbursement have not been verified.

Study clarity

Study start dateStarted: September 2, 2008

Recruitment status: Completed
Enrollment listed in the registry: 461
Sponsor: Shire
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: United States
Age range: From 6 Years to 17 Years
Official registry ID: NCT00734578
Official title: Show the full official title
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center, Dose Optimization Study Evaluating the Efficacy and Safety of SPD503 in Combination With Psychostimulants in Children and Adolescents Aged 6-17 Years With a Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed

Dothan · Scottsdale · Little Rock

53 more locations

FAQ

Who is behind this study?

The study sponsor is Shire.

Did this study involve medication?

Yes. The study involved medication, including SPD503-AM, SPD503-PM and Placebo.

Who was this study for?

Listed age limits: 6 years to 17 years.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.